HealthDay News — For patients with diabetes undergoing percutaneous coronary intervention (PCI), high lipoprotein(a) (Lp[a]) levels are associated with advanced cardiac events, according to a study published in The American Journal of Cardiology.
Hirokazu Konishi, MD, PhD, from Juntendo University Shizuoka Hospital in Japan, and colleagues examined the role of Lp(a) in patients with diabetes who underwent PCI. Data were included for 1136 eligible patients, who were divided into 2 groups based on the median of Lp(a) levels (high Lp[a], 575 patients and low Lp[a], 561 patients). Patients were followed for a median of 4.7 years.
The researchers found that the event rate of all-cause death was not significantly different between the groups. The high Lp(a) group had significantly higher cumulative incidence of cardiac death and acute coronary syndrome than the low Lp(a) group. High Lp(a) was an independent predictor of cardiac death and acute coronary syndrome in multivariable analysis (hazard ratio: 1.2).
“In conclusion, a high Lp(a) value could be associated with advanced cardiac events after PCI for patients with diabetes,” the researchers wrote.
- Knoishi H, Miyauchi K, Shitara J, et al. Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention. Am J Cardiol. 2016;118(12):1781-1785.